bullish

Gland Pharma: Charting New Frontiers Of Growth

132 Views09 Sep 2021 09:20
Broker
We expect revenue and PAT CAGR of 18.2% and 19.7% respectively over FY21-FY24E and recommend a HOLD with TP of Rs 4,100, implying an upside of 3% from CMP.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 1-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Axis Direct
External broker reports(aggregated public sources)
Axis Direct
IndiaEquity Bottom-Up
  • Gland Pharma: Charting New Frontiers Of Growth
    09 Sep 2021
x